Skip to Content
Merck
  • A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.

A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins.

Bioorganic & medicinal chemistry letters (2008-08-19)
Stefan Leyers, Hans-Georg Häcker, Jeanette Wiendlocha, Michael Gütschow, Michael Wiese
ABSTRACT

We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-aminobenzoic acid substructure with 1, also inhibited MRP1. Both derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Indomethacin, meets USP testing specifications
Sigma-Aldrich
Cyclosporin A, BioReagent, from Tolypocladium inflatum, Molecular Biology, ≥95%
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, ≥95% (HPLC), solid
Sigma-Aldrich
Indomethacin, 98.0-102.0%, meets EP testing specifications
Sigma-Aldrich
Cyclosporin A, 97.0-101.5% (on dried basis)
Supelco
Cyclosporin A, VETRANAL®, analytical standard